Vaxcyte (PCVX) Q2 Loss Widens 11%
Vaxcyte (NASDAQ:PCVX), a biotechnology company specializing in next-generation vaccines, reported its second quarter 2025 results on August 6, 2025. The company reported a GAAP net loss per share of $(1.22), missing the consensus estimate of $(1.16). There was no recognized revenue for the quarter, as the company remains pre-commercial. Operating expenses (GAAP) rose sharply compared to Q2 2024 as Vaxcyte boosted research, clinical activities, and manufacturing investments linked to its lead pneumococcal vaccine candidate, VAX-31. Despite the wider loss, Vaxcyte ended the quarter with $2.83 billion in cash and investments, enough to fund operations through mid-2028, based on its cash, cash equivalents, and investments as of June 30, 2025. The quarter was notable for major progress on regulatory milestones and pipeline prioritization but underscored continued high spending and execution risk ahead of pivotal Phase 3 trial results.
Source: Analyst estimates for the quarter provided by FactSet.
Vaxcyte is a clinical-stage vaccine developer harnessing novel technology for more effective, broad-spectrum vaccines. Its XpressCF™ cell-free protein synthesis platform enables precise, large-scale vaccine production without living cells, making it possible to target a wider range of infectious disease threats through its innovative vaccine pipelines.
Source Fool.com
